Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

New Delhi, <keyword id="13247465" type="General" weightage="20" keywordseo="Zydus-Lifesciences" source="Orion">Zydus Lifesciences</keyword> on Tuesday said it has acquired UK-based LiqMeds Group for GBP 68 million (around Rs 689 crore). The Ahmedabad-based group, through its wholly-owned subsidiary Zydus Pharmaceuticals UK Ltd, will also pay yearly earn-outs until 2026 depending on the achievement of certain agreed milestones towards the acquisition. LiqMeds Group of companies specialises in the development, manufacturing and supply of oral liquid products for global markets. The group's subsidiary LM Manufacturing Ltd has an oral liquids manufacturing site at Weedon, Northampton, UK, which supplies products to the US and UK markets. "Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026 depending on the achievement of certain agreed milestones towards the acquisition of the LiqMeds Group of companies," the company said in a regulatory filing. The transaction will be EPS accretive for Zydus from the first year of acquisition, it added. "We believe that liquid orals is a large, growing market and serves unmet needs with significant new market expansion opportunities," Zydus Lifesciences Managing Director Sharvil Patel said. In line with the patient-centric approach, the company believes that oral liquid formulations would help geriatric and paediatric patients, bringing in greater ease of convenience and therapy compliance, he added. Shares of Zydus were trading at 0.89 per cent lower at Rs 574.70 apiece on the BSE.

Zydus Lifesciences acquires UK-based LiqMeds Group for GBP 68 million

New Delhi, <keyword id="13247465" type="General" weightage="20" keywordseo="Zydus-Lifesciences" source="Orion">Zydus Lifesciences</keyword> Ltd on Friday reported over two-fold rise in consolidated net profit at Rs 1,086.9 crore for the first quarter ended June 30, 2023 driven by strong sales growth from US formulations. The company had posted a net profit of Rs 518.3 crore for the same quarter last fiscal, Zydus Lifesciences said in a regulatory filing. Revenue from operations during the quarter under review stood at Rs 5,139.6 crore as against Rs 3,964.4 crore in the year-ago period, up 29.6 per cent. India geography clocked sales of Rs 1,920.6 crore in the first quarter as compared to Rs 1,816.7 crore in the corresponding period a year ago. Sales from US formulations were at Rs 2,454.1 crore as compared to Rs 1,559.2 crore in the same quarter a year ago, up 57.4 per cent, the company said. Active pharmaceutical ingredients clocked sales of Rs 138.9 crore in the first quarter as against Rs 122.4 crore in the corresponding quarter last fiscal, it added. During the quarter, the company witnessed a broad-based operational growth in its key businesses and a favourable product mix enhanced profitability, Zydus Lifesciences Managing Director Sharvil Patel said. "Strong execution and volume offtake drove revenue ramp-up in the US, while the India branded formulations business, adjusting for NLEM (national list of essential medicines) impact delivered solid 12 per cent growth," he added. On the outlook, he said,"We remain reassured on achieving profitable growth aspirations for the fiscal year and thereby enhance stakeholder value."

Zydus Lifesciences Q1 2023-24 profit up 2-fold at Rs 1,087 cr

<ul><li>The <keyword id="6354458" type="UNKNOWN" weightage="20" keywordseo="US">US</keyword> Department of Health and Human Services (HHS) has secured more than 500,000 treatment courses of the drug for American hospitals through September.</li><li>This represents 100 per cent of Gilead's projected production for July (94,200 treatment courses), 90 per cent of production in August (174,900 treatment courses), and 90 per cent of production in September (232,800 treatment courses), in addition to an allocation for clinical trials.</li></ul> The Donald Trump administration has secured nearly the entire world stock of antiviral drug <keyword id="8775508" type="UNKNOWN" weightage="20" keywordseo="remdesivir">remdesivir</keyword> from US-based Gilead Sciences for the next three months, leaving hardly any stock of the key Covid-19 drug for the rest of the world. As a result of an agreement with the drug maker announced earlier this week, the US Department of Health and Human Services (HHS) has secured more than 500,000 treatment courses of the drug for American hospitals through September. This represents 100 per cent of Gilead's projected production for July (94,200 treatment courses), 90 per cent of production in August (174,900 treatment courses), and 90 per cent of production in September (232,800 treatment courses), in addition to an allocation for clinical trials. A treatment course of remdesivir is, on average, 6.25 vials, the US Health and Human Services said. The agreement allows hospitals in the US to purchase the drug in amounts allocated by HHS and state health departments. Hospitals in the US will receive the product shipped by AmerisourceBergen and will pay no more than Gilead's Wholesale Acquisition Price (WAC), which amounts to approximately $3,200 per treatment course. "President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19," US Health and Human Services Secretary Alex Azar said in a statement. "To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump Administration is doing everything in our power to learn more about life-saving therapeutics for COVID-19 and secure access to these options for the American people." Remdesivir is considered a key drug in the fight against Covid-19 as a randomised clinical trial conducted with the drug on 1,063 patients over 60 centres across US, Europe and Asia demonstrated a faster time to clinical recovery in hospitalised patients as compared to placebo. To expand supply of remdesivir, Gilead earlier announced non-exclusive voluntary licensing agreements with generic pharmaceutical manufacturers based in India, Egypt and Pakistan The agreements allow the companies -- Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Eva Pharma; Ferozsons Laboratories; Hetero Labs Ltd.; Jubilant Lifesciences; Mylan; Syngene, a Biocon company; and Zydus Cadila Healthcare Ltd. -- to manufacture remdesivir for distribution in 127 countries. The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access. The regulatory approval status of remdesivir varies by country, and the distribution of remdesivir within each country is subject to local laws and regulations. Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly. The licensees also set their own prices for the generic product they produce. The licenses are royalty-free until the World Health Organization declares the end of the Public Health Emergency of International Concern regarding Covid-19, or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent Covid-19, whichever is earlier.

US secures almost entire world stock of Covid-19 drug remdesivir from Gilead Sciences for the next three months

<ul><li><keyword id="4764339" type="General" weightage="20" keywordseo="drug-shortages" source="Orion">Drug shortages</keyword>, channel realignment and woes of competitors to aid US business of <keyword id="58106" type="General" weightage="20" keywordseo="indian-pharma" source="Orion">Indian pharma</keyword> cos.</li><li>Dr Reddy’s, Cipla, Zydus and Sun Pharmaceuticals gained from sales of generic cancer drugs in the US.</li><li>US FDA inspections are in full swing and the accelerating pace of new launches will improve outlook for US business in FY24, say analysts. </li></ul>The Indian pharma sector has gone through many ups and downs in the last few years – like falling from a Covid-high last year, adding to pricing pressures in its most important market. In the first quarter of FY24 however some of the US market pricing pressures are easing, making up for the slump in domestic sales. “Q1 FY24 turned out to be a tale of two divergent performances as US delivered across the board beat while domestic business, specifically acute, saw weakness in June. Price erosion came in at high single digit in US versus mid-teens last year reflecting in better US revenue growth and profitability,” said a report by YES Securities. Drug shortages, channel realignment and financial as well as regulatory woes of competitors seems to have helped curb US market price erosion in Q1 on a quarter-on-quarter, say analysts. The US market has been dented in the last few years for many reasons including pricing pressures — like supply chain disruptions, and a massive delay in approval of Abbreviated New Drug Applications (ANDAs) leading to fewer generic launches in the US. However, the ability to launch the generic version of a cancer drug gRevlimid in the US abated some of the concerns. Dr Reddy’s generated sales to the tune of $125 million from this generic in Q1 while Cipla, Zydus and Sun Pharmaceuticals reported gRevlimid sales between 40-60 million. “We believe the earnings support from gRevlimid is expected to drive the US base business and abate pricing pressure for the coming two years. Moreover, US FDA inspections are in full swing and the accelerating pace of new launches will improve outlook for US business in FY24,” J M Financial. Lupin and Zydus Life benefitted from exclusive launches of gSuprep and gTrokendi. Darunavir and gSpiriva are other drugs in the pipeline that can boost North America sales of Indian pharma companies. <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;" class="redcator-table-advance"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Stock </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Growth levers ahead </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Sun Pharma </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Specialty performance </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddys </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Revlimid contribution to sustain in 2Q </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus Lifesciences </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Near-term US outlook promising </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">US base biz at $210- 215 mn hereon: mgmt </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Lupin </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Attractive launch pipeline </td></tr></tbody><tbody></tbody><tbody></tbody></table>Source: J M Financial Sun shines in the <keyword id="6382118" type="General" weightage="20" keywordseo="domestic-market" source="Orion">domestic market</keyword> The domestic <keyword id="101756" type="General" weightage="20" keywordseo="pharma-market" source="Orion">pharma market</keyword> seems to see the after-effects of a delayed monsoon, which led to weakness in acute therapies like gastroenteritis which aids seasonal sales in Q1. This trend impacted key players like Dr Reddy’s, JB Chemicals and Alkem. Alkem however said that there has been no change in domestic sales even in July, August is expected to provide some quality on the same. Sun Pharma, however, is an outlier with a good performance in the domestic business as it boosted its sales strength along with new launches. It launched 105 new products in FY23 as compared to 77 new launches the year before. “Sun’s India business has grown at 11% compounded annual growth rate (CAGR) over FY20-23, driven by volume, price and new launches. We expect Sun’s India business to grow at around 10% CAGR over FY23-26,” said a report by IIFL Securities. <div type="javascript" title="Custom" contenttype="Text"><cdata><![CDATA[]]></cdata></div>

You Searched For "Zydus Lifesciences stocks" and got 4 results

Zydus Lifesciences acquires UK-based LiqMeds Group for GBP 68 million

PTI

Zydus Lifesciences Q1 2023-24 profit up 2-fold at Rs 1,087 cr

PTI

US secures almost entire world stock of Covid-19 drug remdesivir from Gilead Sciences for the next three months

IANS

US outlook improves for Indian pharma but domestic market under the cloud

Katya Naidu

Popular Keywords

Buying Guides